康莱特注射液联合化疗治疗非小细胞肺癌的效果及对T淋巴细胞亚群的影响

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Kanglaite Injection combined with chemotherapy regimen in the treatment of non-small cell lung cancer and its influence on the level of T lymphocyte subsets and inflammatory factors.Methods Sixty-eight non-small cell lung cancer patients admitted to our hospital from April 2015 to August 2017 were selected and divided into the observation group and the control group according to the random number table method,34 cases in each group.The observation group was given Kanglaite Injection+the GP regimen,and the GP regimen was used to treat the patients in the control group,and 21 d for 1 courses,continuous treatment for 3 courses.Clinical efficacy,T-lymphocyte subsets,inflammatory factors,quality of life,and adverse reactions were observed in the both groups.Results The clinical remission rate in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P＜0.05).After treatment,the levels of CD3,CD4,CD8,and CD4/CD8 in the observation group were significantly higher than that in the control group,the difference was statistically significant(P＜0.05).After treatment,the levels of IL-2,IL-6 and TNF-α in the observation group were significantly lower than that in the control group,and the difference was statistically significant(P＜0.05).The scores of somatic function,material function,social function,and psychological function in the observation group were significantly higher than those in the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups during treatment(P＞0.05).Conclusion Kanglaite Injection-assisted GP regimen is effective in the treatment of non-small cell lung cancer,which can significantly improve the patient′s immune function,reduce the level of inflammation,improve the patient′s quality of life,and it is worthy of clinical promotion.

Key words： Kanglaite injection GP regimen Non-small cell lung cancer Immune function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	NING Shang-fu

Cite this article:

NING Shang-fu. Effect of Kanglaite Injection combined with chemotherapy in the treatment of non-small cell lung cancer and its influence on T lymphocyte subsets[J]. 中国当代医药, 2018, 25(29): 18-21.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I29/18

[1]	李骁，王文萍.康莱特注射液治疗中晚期非小细胞肺癌有效性及安全性Meta分析[J].辽宁中医药大学学报，2017，19（3）：170-173.
[2]	鲁小敏，张燕，吉浩明，等.康莱特注射液联合化疗对晚期非小细胞肺癌疗效及免疫功能的影响[J].江苏医药，2016，42（9）：1068-1070.
[3]	刘雪娇.康莱特联合化疗治疗中晚期非小细胞肺癌临床疗效观察[J].临床军医杂志，2017，45（3）：265-268.
[4]	龙圣根，肖玉兰.康莱特与GP方案联用对晚期非小细胞肺癌患者的临床疗效及其对免疫功能各指标的影响[J].抗感染药学，2017，14（2）：377-380.
[5]	余蕊，叶赟，申光富，等.康莱特注射液对非小细胞肺癌的疗效及对T淋巴细胞亚群的影响[J].世界中医药，2016，11（10）：1997-2001.
[6]	赵文婷，白静慧.康莱特注射液对老年非小细胞肺癌的临床研究[J].辽宁医学杂志，2017，31（6）：32-34.
[7]	朱佳佳，尤寅骏.康莱特注射液联合GP方案对晚期非小细胞肺癌患者免疫功能的改善作用[J].河南中医，2016，36（11）：1943-1945.
[8]	陈维，魏涛.康莱特注射液联合吉西他滨顺铂方案治疗晚期非小细胞肺癌的临床疗效及对患者免疫功能的影响[J].中国肿瘤临床与康复，2016，23（7）：814-817.
[9]	王媛，惠双，李敏，等.康莱特注射液用于吉西他滨联合顺铂方案化疗晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志，2017，33（23）：2354-2356，2360.
[10]	侯恩存，陈杰，甘露，等.康莱特联合GP方案治疗晚期非小细胞肺癌疗效的系统评价[J].现代肿瘤医学，2015，23（7）：960-965.
[11]	贾锐，唐琼，赵辉.康莱特在老年晚期非小细胞肺癌化疗中的应用效果[J].医学信息，2016，29（17）：85.
[12]	姚德蛟.康莱特联合吉西他滨、顺铂治疗晚期非小细胞肺癌的临床疗效及安全性评价[J].中国临床药理学杂志，2015，31（15）：1494-1496.
[13]	邓新娜，赵淑芳，李阳，等.康莱特注射液联合化疗治疗老年晚期非小细胞肺癌疗效观察[J].现代中西医结合杂志，2015，24（18）：1951-1953，1957.
[14]	宁加亮，祝福琼，高迎春.吉非替尼联合康莱特治疗对晚期非小细胞肺癌患者免疫功能及生活质量的影响[J].现代肿瘤医学，2015，23（14）：1976-1979.
[15]	付鹏，李翔，王超，等.康莱特注射液在中晚期非小细胞肺癌治疗中的临床应用研究[J].癌症进展，2016，14（3）：266-268，271.
[16]	杭猛，陈暑波，孙清，等.GP方案联合康莱特注射液治疗晚期非小细胞肺癌的疗效及安全性分析[J].实用癌症杂志，2017，32（2）：289-291.
[17]	陈伟伟，雷励，蔡少华，等.康莱特注射液联合化疗治疗晚期非小细胞肺癌的临床疗效[J].现代生物医学进展，2015，15（20）：3869-3871，3885.
[18]	马宣，周玮.康莱特注射液对晚期非小细胞肺癌患者免疫功能及生活质量的影响[J].中药药理与临床，2015，31（2）：184.